Your browser doesn't support javascript.
COVID-19 mRNA vaccine effectiveness (second and first booster dose) against hospitalisation and death during Omicron BA.5 circulation: cohort study based on electronic health records, Portugal, May to July 2022.
Kislaya, Irina; Machado, Ausenda; Magalhães, Sarah; Rodrigues, Ana Paula; Franco, Rafael; Leite, Pedro Pinto; Dias, Carlos Matias; Nunes, Baltazar.
  • Kislaya I; Departamento de Epidemiologia, Instituto Nacional de Saúde Doutor Ricardo Jorge, Lisbon, Portugal.
  • Machado A; Centro de Investigação em Saúde Pública, Escola Nacional de Saúde Pública, Universidade NOVA de Lisboa, Lisbon, Portugal.
  • Magalhães S; Departamento de Epidemiologia, Instituto Nacional de Saúde Doutor Ricardo Jorge, Lisbon, Portugal.
  • Rodrigues AP; Centro de Investigação em Saúde Pública, Escola Nacional de Saúde Pública, Universidade NOVA de Lisboa, Lisbon, Portugal.
  • Franco R; Serviços Partilhados do Ministério da Saúde, Lisbon, Portugal.
  • Leite PP; Departamento de Epidemiologia, Instituto Nacional de Saúde Doutor Ricardo Jorge, Lisbon, Portugal.
  • Dias CM; Serviços Partilhados do Ministério da Saúde, Lisbon, Portugal.
  • Nunes B; Direção de Serviços de Informação e Análise, Direção-Geral da Saúde, Lisbon, Portugal.
Euro Surveill ; 27(37)2022 09.
Article in English | MEDLINE | ID: covidwho-2039628
ABSTRACT
We measured vaccine effectiveness (VE) against COVID-19-related severe outcomes in elderly people in Portugal between May and July 2022. In ≥ 80 year-olds, the second booster dose VE was 81% (95% CI 75-85) and 82% (95% CI 77-85), respectively, against COVID-19-related hospitalisation and death. The first booster dose VE was 63% (95% CI 55-70) in ≥ 80 year-olds and 74% (95% CI 66-80) in 60-79 year-olds against hospitalisation, and 63% (95% CI 57-69) and 65% (95% CI 54-74) against death.
Subject(s)
Keywords
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: Available Collection: International databases Database: MEDLINE Main subject: COVID-19 Vaccines / COVID-19 Type of study: Cohort study / Experimental Studies / Observational study / Prognostic study Topics: Vaccines / Variants Limits: Aged / Humans Country/Region as subject: Europa Language: English Journal subject: Communicable Diseases Year: 2022 Document Type: Article Affiliation country: 1560-7917.ES.2022.27.37.2200697

Similar

MEDLINE
LILACS
LIS
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: Available Collection: International databases Database: MEDLINE Main subject: COVID-19 Vaccines / COVID-19 Type of study: Cohort study / Experimental Studies / Observational study / Prognostic study Topics: Vaccines / Variants Limits: Aged / Humans Country/Region as subject: Europa Language: English Journal subject: Communicable Diseases Year: 2022 Document Type: Article Affiliation country: 1560-7917.ES.2022.27.37.2200697